Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Current Leases (2019 - 2025)

Ultragenyx Pharmaceutical has reported Current Leases over the past 7 years, most recently at $12.0 million for Q4 2025.

  • Quarterly Current Leases rose 20.0% to $12.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.0 million through Dec 2025, up 20.0% year-over-year, with the annual reading at $12.0 million for FY2025, 20.0% up from the prior year.
  • Current Leases was $12.0 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $12.1 million in the prior quarter.
  • Over five years, Current Leases peaked at $12.8 million in Q1 2024 and troughed at $9.4 million in Q1 2021.
  • The 5-year median for Current Leases is $11.5 million (2022), against an average of $11.3 million.
  • Year-over-year, Current Leases skyrocketed 37.42% in 2021 and then decreased 20.6% in 2024.
  • A 5-year view of Current Leases shows it stood at $11.1 million in 2021, then rose by 6.44% to $11.8 million in 2022, then grew by 6.93% to $12.6 million in 2023, then decreased by 20.6% to $10.0 million in 2024, then increased by 20.0% to $12.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Current Leases are $12.0 million (Q4 2025), $12.1 million (Q3 2025), and $11.8 million (Q2 2025).